Why the study?
Does prenatal exposure to paroxetine cause adverse neonatal outcomes in premature twins?
Case Report (n=2)
No
Does prenatal exposure to paroxetine cause adverse neonatal outcomes in premature twins?
This is the authors' abstract. We don't add key points for this paper.
Two premature twins (33 weeks gestation) were born to a woman who had used paroxetine during pregnancy for an anxiety-depression disorder. They were admitted to the NICU, where they showed prolonged RDS, cardiovascular malformations, and facial dysmorphisms. Soon after birth, they also presented abnormal neurobehavioral and motor signs, which partially disappeared during the following weeks, although alterations of tone persisted even at discharge. Selective serotonin reuptake inhibitor (SSRI) antidepressants are considered the primary treatments for depression and anxiety in pregnancy. Since intrauterine exposure to these drugs has been associated with poor neonatal adaptation, low birth weight, RDS, neurobehavioural symptoms, and potential teratogenic effects, further studies are needed to assess risks and mechanism of action of SSRIs. Meanwhile, it is advisable to evaluate for each patient the real risk/benefit ratio of continuing or suspending treatment during pregnancy.
Answers are grounded in this paper and cite their sources.
Prenatal exposure to paroxetine may be associated with adverse neonatal outcomes including cardiovascular malformations and neurobehavioral symptoms, highlighting the need to weigh risks and benefits of SSRI use during pregnancy.
No takes yet. Share an insight, caveat, or question.
Marsella et al. (2010) conducted a case report in Prenatal exposure to SSRIs (n=2). Paroxetine was evaluated on Clinical presentation (neonatal abstinence syndrome, cardiovascular malformations, respiratory distress).
Synapse has enriched 10 related papers. Consider them for comparative context: